Skip To Main Content
Jieer Ying on Muck Rack

Jieer Ying

As seen in: Frontiers in Immunology, PeerJ, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jieer

Contact Jieer, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Exploratory genomic stratification of benefit from first-line immunotherapy-based combination in advanced biliary tract cancer: a biomarker analysis of a randomized phase 2 trial

|
By Zeyu Ruan, Xiaoqing Xu, Yue Han, Junrong Yan, Qi Xu, Jieer Ying, Shurui Zhou, Yatong He, Jiaojiao Ni
| Frontiers in Immunology
Abstract Background: Benefit from first-line immunotherapy-based treatment in advanced biliary tract cancer (BTC) is heterogeneous, and selection biomarkers are lacking. We investigated whether genomic features could stratify benefit from intensified immunotherapy-based treatment versus chemotherapy.
Open in Who Shared Issue with article?

Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma

|
By Zhi Peng, Jia Wei, Feng Wang, Jieer Ying
| AACR Journal
Research Article Zhi Peng, Jia Wei, Feng wang, Jieer Ying, Yanhong Deng, Kangsheng Gu, Ying Cheng, Xianglin Yuan, Juxiang Xiao, Yanfei Tai, Linna Wang, Jian Jun Zou, Yanqiao Zhang and Lin Shen DOI: 10.1158/1078-0432.CCR-20-4691 Abstract Purpose: Capecitabine plus oxaliplatin (CAPOX) is one of standard first-line treatments for unresectable, advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
Open in Who Shared Issue with article?

Tumor clinicopathological characteristics and their prognostic value in mucinous colorectal carcinoma

|
By Cong Luo, Xiaohong Wang, Shuyi Cen, Jieer Ying
| Future Medicine Verified
Future OncologyAhead of Print Research Article Cong Luo‡ *Author for correspondence: Tel.: +86 134 5671 1894; Fax: +86 571 8812 2082; E-mail Address: congluo939291@163.com https://orcid.org/0000-0002-4415-1666 Department of Abdominal Oncology, Institute of Cancer Research & Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang 310022, PR China , , Jieer Ying Department of Abdominal Oncology,...
Open in Who Shared Issue with article?
See all 3 articles